Business Wire

CES 2022: Seoul Semiconductor to Exhibit All Light Sources Including MICRO DISPLAY Required for Autonomous Driving of Future Vehicle

22.12.2021 07:44:00 EET | Business Wire | Press release

Share

At CES 2022, Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a global optical semiconductor company, will demonstrate a Micro Display for vehicle (WICOP mc) to communicate with pedestrians or oncoming drivers during autonomous driving, and a solution to sterilize the in-vehicle air. In addition, the company will demonstrate WICOP ADB (Adaptive Driving Beam: Intelligent Headlamp), which improves the visibility of oncoming vehicles or pedestrians while driving. WICOP, the basic technology of these two solutions (WICOP mc and WICOP ADB), has already been applied to about 10% of vehicles worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211221005796/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Differences between the 1st and 2nd generation of WICOP technology, products named COB or CSP produced by technology theft (Graphic: Business Wire)

So far, the focus has been on developing technologies for preventing automobile accidents and ensuring driver safety. However, technology that prioritizes the convenience and safety of not only drivers but also passengers, pedestrians, bicycle riders, or other vehicle drivers is becoming very important. In particular, along with automobile indoor sterilization technology to make the air inside a vehicle safe, the lighting communication technology, which can reassure drivers of other vehicles or pedestrians when the driver of an autonomous vehicle is either absent or distracted, is receiving great attention.

With the development of autonomous driving systems, the technology that allows vehicles to recognize surrounding objects is also in the process of development. By the way, the current brightness of LCD or OLED displays less than 1,000 nits has limitations in implementing lighting communication with pedestrians or other vehicles. In addition, the existing LED display chips are large in size, so they cannot properly implement a necessary message on a small bumper or on the exterior of a vehicle. Seoul Semiconductor's dust-proof and moisture-proof WICOP mc realizes a 5000-nits display that is eight times brighter than the existing LCD and can display clear messages.

Seoul Semiconductor is conducting virus sterilization experiments using an actual car in the in-house laboratory to study the safety of passengers from various bacteria and viruses. At CES 2022, Seoul Semiconductor will demonstrate to its VIP customers a solution that can sterilize more than 90% of the viruses floating inside the car within 10 minutes. Seoul Semiconductor will begin mass production of its sterilization technology, Violeds, in January at one of the top five global companies.

"Seoul Semiconductor is the only company in the world that is able to produce and supply a total solution for all light sources from EPI to PKG, from UV LEDs required for automobiles, to Blue, Green, Red, IR LEDs, and even VCSEL laser diodes," a Seoul Semiconductor official said. “At CES 2022, innovation to all solutions will be separately disclosed to VIP customers who have been specially reserved.”

About Seoul Semiconductor

Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phones, computer displays, and other applications, as well as the UV area. The company’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Seoul Semiconductor Co., Ltd.
Jinseop Jeong
+82-70-4391-8555
jjs8732@seoulsemicon.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Together AI and HUMAIN Form Strategic Partnership to Accelerate AI Infrastructure and Cloud Services in Saudi Arabia31.8.2026 15:00:00 EEST | Press release

Together AI, a leading San Francisco-based AI Native Cloud platform, and HUMAIN, a PIF company delivering full-stack artificial intelligence capabilities globally, today at LEAP announced a strategic partnership to connect HUMAIN’s rapidly expanding AI compute capacity in Saudi Arabia with global AI-native and enterprise demand. The partnership will include the construction of a new 250 megawatt data center, located in Saudi Arabia. The partnership brings together HUMAIN’s large-scale, multi-chip AI infrastructure footprint, expanding cloud and inference capabilities with Together AI’s global customer ecosystem and AI-native inference platform. Together, the companies will offer an additional option for developers, enterprises, and AI-native organizations worldwide to access high-performance AI infrastructure for inference and training workloads, all deployed in data centers throughout the Kingdom. “The future of artificial intelligence depends on the ability to combine world-class inf

SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 13:50:00 EEST | Press release

SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions, expands our addressable market — more than doubling our revenue opportunity per gigawatt of delivered capacity — and allows us to scale both our offerings and the globa

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye